Noninvasive Grading of Untreated Gliomas: a Comparative Study of MR Imaging and 3-(iodine 123)-L-alpha-methyltyrosine SPECT
Authors
Affiliations
Purpose: To compare the accuracy of magnetic resonance (MR) imaging scores with that of 3-(iodine 123)-L-alpha-methyltyrosine ((123)I-IMT) single photon emission computed tomography (SPECT) in the noninvasive grading of untreated gliomas.
Materials And Methods: The study comprised 15 patients with low-grade gliomas (grades I-II, according to World Health Organization criteria) and 33 patients with high-grade gliomas (grades III-IV). The lesions were evaluated by using an MR imaging score based on nine criteria. The (123)I-IMT uptake was quantified as the ratio between the amino acid uptake in the tumor and that in the contralateral hemisphere. To test for potentially significant differences in diagnostic performance between contrast material-enhanced MR imaging and (123)I-IMT SPECT, binormal receiver operating characteristic curves were fitted to the data and compared by using the area test.
Results: The accuracy of MR imaging in the noninvasive grading of untreated gliomas was higher than that of (123)I-IMT SPECT (88% vs 79%). However, the difference in diagnostic performance was not significant on the basis of findings at receiver operating characteristic analysis (P >.2). Neither MR imaging nor (123)I-IMT SPECT allowed differentiation between high-grade gliomas (grades III and IV).
Conclusion: Although (123)I-IMT uptake is significantly higher in high-grade gliomas than in low-grade gliomas, the performance of (123)I-IMT SPECT adds little to the accuracy of determining tumor grade when MR imaging is performed.
Yang S, Zhao B, Wang G, Xiang J, Xu S, Liu Y AJNR Am J Neuroradiol. 2016; 37(12):2209-2216.
PMID: 27561831 PMC: 7963858. DOI: 10.3174/ajnr.A4907.
Schafer M, Maurer M, Synowitz M, Wustefeld J, Marnitz T, Streitparth F Eur Radiol. 2013; 23(10):2846-53.
PMID: 23686293 DOI: 10.1007/s00330-013-2886-y.
Hellwig D, Ketter R, Romeike B, Schaefer A, Farmakis G, Grgic A Eur J Nucl Med Mol Imaging. 2010; 37(12):2344-53.
PMID: 20676638 DOI: 10.1007/s00259-010-1572-4.
Management of newly diagnosed glioblastoma: guidelines development, value and application.
Olson J, Fadul C, Brat D, Mukundan S, Ryken T J Neurooncol. 2009; 93(1):1-23.
PMID: 19430879 DOI: 10.1007/s11060-009-9838-z.
Neuroradiological assessment of newly diagnosed glioblastoma.
Mukundan S, Holder C, Olson J J Neurooncol. 2008; 89(3):259-69.
PMID: 18712280 DOI: 10.1007/s11060-008-9616-3.